Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience

• Older patients with T2DM are often excluded from randomized controlled trials. • The insulin-independent mechanism of action makes SGLT2i suitable in the elderly. • Our study focused on SGLT2i-treated older patients with T2DM, stratified by age (65–69 and ≥70 years). • HbA1c reduction, eGFR variat...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients. - 2016. - Amsterdam [u.a.]
1. Verfasser: Tumminia, Andrea (VerfasserIn)
Weitere Verfasser: Graziano, Marco (BerichterstatterIn), Vinciguerra, Federica (BerichterstatterIn), Lomonaco, Andrea (BerichterstatterIn), Frittita, Lucia (BerichterstatterIn)
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
Schlagworte:Type 2 diabetes Elderly Sodium-glucose cotransporter 2 inhibitors Real-world evidence
Umfang:6
LEADER 01000caa a22002652 4500
001 ELV053262956
003 DE-627
005 20230624193341.0
007 cr uuu---uuuuu
008 210910s2021 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.pcd.2020.10.002  |2 doi 
028 5 2 |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001496.pica 
035 |a (DE-627)ELV053262956 
035 |a (ELSEVIER)S1751-9918(20)30287-4 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
082 0 4 |a 630  |q VZ 
082 0 4 |a 640  |q VZ 
082 0 4 |a 590  |q VZ 
082 0 4 |a 610  |q VZ 
082 0 4 |a 600  |q VZ 
084 |a 50.70  |2 bkl 
100 1 |a Tumminia, Andrea  |e verfasserin  |4 aut 
245 1 0 |a Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience 
264 1 |c 2021 
300 |a 6 
336 |a nicht spezifiziert  |b zzz  |2 rdacontent 
337 |a nicht spezifiziert  |b z  |2 rdamedia 
338 |a nicht spezifiziert  |b zu  |2 rdacarrier 
520 |a • Older patients with T2DM are often excluded from randomized controlled trials. • The insulin-independent mechanism of action makes SGLT2i suitable in the elderly. • Our study focused on SGLT2i-treated older patients with T2DM, stratified by age (65–69 and ≥70 years). • HbA1c reduction, eGFR variation and tolerability were similar across age groups. • Among elderly T2DM individuals, SGLT2i are effective, safe and fairly well tolerated. 
650 7 |a Type 2 diabetes  |2 Elsevier 
650 7 |a Elderly  |2 Elsevier 
650 7 |a Sodium-glucose cotransporter 2 inhibitors  |2 Elsevier 
650 7 |a Real-world evidence  |2 Elsevier 
700 1 |a Graziano, Marco  |4 oth 
700 1 |a Vinciguerra, Federica  |4 oth 
700 1 |a Lomonaco, Andrea  |4 oth 
700 1 |a Frittita, Lucia  |4 oth 
773 0 8 |i Enthalten in  |n Elsevier  |a David, Lauren A. ELSEVIER  |t A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients  |d 2016  |g Amsterdam [u.a.]  |w (DE-627)ELV024210129 
773 1 8 |g volume:15  |g year:2021  |g number:2  |g pages:283-288  |g extent:6 
856 4 0 |u https://doi.org/10.1016/j.pcd.2020.10.002  |3 Volltext 
912 |a GBV_USEFLAG_U 
912 |a GBV_ELV 
912 |a SYSFLAG_U 
912 |a GBV_ILN_24 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_227 
912 |a GBV_ILN_350 
936 b k |a 50.70  |j Energie: Allgemeines  |q VZ 
951 |a AR 
952 |d 15  |j 2021  |e 2  |h 283-288  |g 6